Literature DB >> 12624424

A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I.

Klara Sjögren1, John-Olov Jansson, Olle G P Isaksson, Claes Ohlsson.   

Abstract

Insulin-like growth factor-I (IGF-I) has important growthpromoting and metabolic effects and is expressed in virtually every tissue of the body. The highest expression is found in the liver, but the physiological role of liver-derived IGF-I is unknown. It has been difficult to separate the endocrine effects of liver-derived IGF-I from the autocrine/paracrine effects of locally produced IGF-I in peripheral tissues. Therefore, we have developed a mouse model with a liver-specific inducible deletion of the IGF-I gene (LI-IGF-I-/- mouse). The LI-IGF-I-/- mouse has dramatically reduced (>80%) serum IGF-I levels, demonstrating that the major part of serum IGF-I is liver-derived. Surprisingly, LI-IGFI -/- mice demonstrate a normal appendicular skeletal growth up to at least 12 mo of age despite the dramatic decrease in circulating IGF-I levels, indicating that liver-derived IGF-I is not required for appendicular skeletal growth. However, the adult axial skeletal growth is reduced in the LI-IGF-I-/- mice. Furthermore, the amount of cortical bone is reduced due to decreased radial growth of the cortical bone, while the trabecular bone mineral density is unchanged in the LI-IGFI -/- mice. The decreased levels of circulating IGF-I are associated with increased serum levels of growth hormone (GH), indicating a role for liver-derived IGFI in the negative-feedback regulation of GH secretion. Measurements of factors regulating GH secretion in the pituitary and in the hypothalamus revealed an increased expression of GH-releasing-hormone (GHRH) and GHsecretagogue (GHS) receptors in the pituitary of LI-IGFI -/- mice. This in turn results in an increased sensitivity to systemically administered GHRH and GHS, demonstrating that the regulatory action of liver-derived IGF-I on GH secretion is at the pituitary rather than at the hypothalamic level. The liver is an important metabolic organ and LI-IGF-I-/- mice are markedly hyperinsulinemic and yet normoglycemic, consistent with an adequately compensated insulin resistance. Interestingly, LI-IGF-I-/- mice display a reduced age-dependent fat mass accumulation compared with control mice. Furthermore, LI-IGF-I-/- mice have increased blood pressure attributable to increased peripheral resistance indicating a role for liver-derived IGF-I in the regulation of blood pressure. In conclusion, liver-derived IGF-I is important for carbohydrate and lipid metabolism and for the regulation of GH secretion at the pituitary level. Furthermore, it regulates adult axial skeletal growth and cortical radial growth while it is not required for appendicular skeletal growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12624424     DOI: 10.1385/ENDO:19:3:249

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  73 in total

1.  Liver-derived IGF-I regulates GH secretion at the pituitary level in mice.

Authors:  K Wallenius; K Sjögren; X D Peng; S Park; V Wallenius; J L Liu; M Umaerus; H Wennbo; O Isaksson; L Frohman; R Kineman; C Ohlsson; J O Jansson
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

2.  Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats.

Authors:  G Pete; Y Hu; M Walsh; J Sowers; J C Dunbar
Journal:  Proc Soc Exp Biol Med       Date:  1996-11

3.  A putative GTP binding protein homologous to interferon-inducible Mx proteins performs an essential function in yeast protein sorting.

Authors:  J H Rothman; C K Raymond; T Gilbert; P J O'Hara; T H Stevens
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

4.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.

Authors:  Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

5.  Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle.

Authors:  F Frick; J Oscarsson; K Vikman-Adolfsson; M Ottosson; N Yoshida; S Edén
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-04       Impact factor: 4.310

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 7.  Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus.

Authors:  S Minami; J Kamegai; H Sugihara; N Suzuki; I Wakabayashi
Journal:  Endocr J       Date:  1998-04       Impact factor: 2.349

8.  Growth allometry of the organs in giant transgenic mice.

Authors:  B T Shea; R E Hammer; R L Brinster
Journal:  Endocrinology       Date:  1987-12       Impact factor: 4.736

9.  Insulin-like growth factors: a role in growth hormone negative feedback and body weight regulation via brain.

Authors:  G S Tannenbaum; H J Guyda; B I Posner
Journal:  Science       Date:  1983-04-01       Impact factor: 47.728

10.  Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide.

Authors:  M F Walsh; M Barazi; G Pete; R Muniyappa; J C Dunbar; J R Sowers
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

View more
  13 in total

Review 1.  Extrapituitary production of anterior pituitary hormones: an overview.

Authors:  S Harvey; C Arámburo; E J Sanders
Journal:  Endocrine       Date:  2011-11-15       Impact factor: 3.633

Review 2.  Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development.

Authors:  Yongmei Wang; Daniel D Bikle; Wenhan Chang
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

3.  Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model.

Authors:  Christopher J Romero; Yewade Ng; Raul M Luque; Rhonda D Kineman; Linda Koch; Jens C Bruning; Sally Radovick
Journal:  Mol Endocrinol       Date:  2010-03-08

4.  Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo.

Authors:  Jonathan B Hurov; Mei Huang; Lynn S White; Jochen Lennerz; Cheol Soo Choi; You-Ree Cho; Hyo-Jeong Kim; Julie L Prior; David Piwnica-Worms; Lewis C Cantley; Jason K Kim; Gerald I Shulman; Helen Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  Muscle-specific growth hormone receptor (GHR) overexpression induces hyperplasia but not hypertrophy in transgenic zebrafish.

Authors:  Marcio Azevedo Figueiredo; Edson A Mareco; Maeli Dal Pai Silva; Luis Fernando Marins
Journal:  Transgenic Res       Date:  2011-08-24       Impact factor: 2.788

6.  Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet.

Authors:  Yu-Kun Jennifer Zhang; Kai Connie Wu; Jie Liu; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-24       Impact factor: 4.219

7.  Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles.

Authors:  Edward O List; Darlene E Berryman; Kevin Funk; Adam Jara; Bruce Kelder; Feiya Wang; Michael B Stout; Xu Zhi; Liou Sun; Thomas A White; Nathan K LeBrasseur; Tamara Pirtskhalava; Tamara Tchkonia; Elizabeth A Jensen; Wenjuan Zhang; Michal M Masternak; James L Kirkland; Richard A Miller; Andrzej Bartke; John J Kopchick
Journal:  Endocrinology       Date:  2014-02-11       Impact factor: 4.736

8.  Effect of fat supplementation on leptin, insulin-like growth factor I, growth hormone, and insulin in cattle.

Authors:  Damasia Becú-Villalobos; Isabel García-Tornadú; Guillermo Shroeder; Eloy E Salado; Gerardo Gagliostro; Carole Delavaud; Yves Chilliard; Isabel M Lacau-Mengido
Journal:  Can J Vet Res       Date:  2007-07       Impact factor: 1.310

9.  Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism.

Authors:  Yong Fan; Ram K Menon; Pinchas Cohen; David Hwang; Thomas Clemens; Douglas J DiGirolamo; John J Kopchick; Derek Le Roith; Massimo Trucco; Mark A Sperling
Journal:  J Biol Chem       Date:  2009-05-21       Impact factor: 5.157

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.